NORPACE 150mg Price

Overview

Welcome to Dwaey, specifically on NORPACE 150mg page.
This medicine contains an important and useful components, as it consists of
Disopyramide phosphateis available in the market in concentration

Name

Disopyramide

Precaution

Conduction disorders or uncompensated heart failure. Pregnancy and lactation. Renal and hepatic failure. Family history of glaucoma. Correct potassium deficiency. Lactation: crosses into breast milk, discontinue drug or do not nurse

Indication

Ventricular tachycardia, Supraventricular and Ventricular arrhythmias

Contra indication

Patients with complete heart block; glaucoma; predisposition to urinary retention; myasthenia gravis. Sinus node disease in absence of pacemaker. Cardiomyopathy. Cardiogenic shock. Hypotension. Hypersensitivity. Children.

Side Effect

>10% Xerostomia (32%),Urinary hesitancy (23%),Constipation (11%) 1-10% Impotence,Urinary urgency,Urinary retention,Dry throat,Weight gain,Abdominal distension,Flatulence,Anorexia,Vomiting,Nausea,Dermatoses,Pruritus,Generalized rash,Increased triglycerides and cholesterol,Hypokalemia,Muscle weakness,Muscular pain,Dyspnea,Blurred vision,Dry eyes,Fatigue,Malaise,Headache,Dizziness,Nervousness,Syncope,Hypotension,Chest pain,Edema <1% AV block,Hypoglycemia (rare),Agranulocytosis,Respiratory distress,Creatinine increased,Psychotic reaction,Paresthesia,Lupus (rare),Peripheral neuropathy,Insomnia Potentially Fatal: Urinary retention, severe cardiovascular depression if given as rapid IV inj. High risk of recurrence of failure in patients with history of congestive cardiac failure. Negative inotropic effect especially prominent in patients with cardiomyopathy, hypertension and uncompensated cardiac failure.

Pregnancy Category ID

3

Mode of Action

Disopyramide is a Ia antiarrhythmic agent which acts by decreasing myocardial excitability and conduction velocity. It lengthens the effective refractory period of the atrium. It also possesses antimuscarinic and negative inotropic effects.

Interaction

Avoid other Class I antiarrhythmics and other cardiac depressants including beta-blockers except in life-threatening arrhythmias. Risk of worsening of arrhythmias, precipitation of new arrhythmias and ventricular fibrillation when used with other anti-arrhythmics. Reduced efficacy when co-admin with phenytoin. Potentially Fatal: Enhanced antimuscarinic effects with other antimuscarinic drugs. Potentiates negative chronotropic and inotropic effects of ?-blockers and verapamil. Potentiates inhibitory effect on the conduction system produced by digitalis. Potentiates QT interval prolongation produced by TCAs and amiodarone.

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration